FIELD: medicine.
SUBSTANCE: invention claims application of therapeutically effective quantity of Bifidobacteria lactis Bb-12 and Lactibacillus rhamnosus GG, where effective quantity of Bb-12 and LGG is ca. 105 to 1011 colony-forming units, and Bb-12 to LGG ratio is ca. 10:1 to 1:10.
EFFECT: non-medicated treatment method or respiratory infection risk reduction for babies.
6 cl, 2 ex, 4 tbl, 2 dwg
Authors
Dates
2008-08-27—Published
2005-07-01—Filed